Valeant Pharmaceuticals International
Worldwide Headquarters
One Enterprise
Aliso Viejo
California
92656
United States
Tel: 800-548-5100 or 949-461-6000
Fax: 714-556-0131
Website: http://www.valeant.com/
About Valeant Pharmaceuticals International
Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.YEAR FOUNDED:
1960
LEADERSHIP:
CEO: Joseph C. Papa
CMO: Tage Ramakrishna
CFO: Robert Rosiello
CLINICAL TRIAL:
Please click here for clinical trial information.
JOB OPPORTUNITY:
Please click here for Valeant job opportunities.
953 articles about Valeant Pharmaceuticals International
-
Valeant Pharmaceuticals International Developing Intranasal Diazepam For The At-Home Treatment Of Emergency Seizures
1/25/2007
-
Valeant Pharmaceuticals International Files Restated Financial Statements And September 30, 2006 Form 10-Q
1/23/2007
-
Valeant Pharmaceuticals International Signs Licensing Agreement For Canadian Rights To (C)Xyrem(R) (Sodium Oxybate) From Jazz Pharmaceuticals, Inc.
1/12/2007
-
Valeant Pharmaceuticals International And Metabasis Therapeutics, Inc. Close Licensing Deal With Schering-Plough Corporation
1/11/2007
-
Valeant Pharmaceuticals International & Metabasis Therapeutics, Inc. Close Licensing Deal With Schering-Plough Corporation
1/11/2007
-
The Day In Review: SciClone Pharmaceuticals, Inc. Soars On Positive Melanoma Results
12/22/2006
-
Valeant Pharmaceuticals International To Relocate Worldwide Corporate Headquarters
12/21/2006
-
Valeant Pharmaceuticals International And Metabasis Therapeutics, Inc. License Rights To Hepatitis B Compound Pradefovir To Schering-Plough Corporation
12/14/2006
-
Valeant Pharmaceuticals International Initiates Infergen(R) Phase 4 Study
12/12/2006
-
Dendrite International, Inc. Helps Valeant Pharmaceuticals International Enhance Sales Force Effectiveness In Latin America
11/27/2006
-
Valeant Pharmaceuticals International Reports Preliminary 2006 Third Quarter Financial Information
11/2/2006
-
Par Pharmaceutical Companies, Inc. Announces Termination Of Cesamet(TM) Promotion Agreement
11/2/2006
-
Valeant Pharmaceuticals International Presents End-Of-Treatment Results Of DIRECT Trial For Infergen At The American Association for Study of Liver Diseases 2006 Annual Meeting
10/30/2006
-
Valeant Pharmaceuticals International To Restate Certain Financial Statements Due To Stock Option Accounting Review
10/23/2006
-
Valeant Pharmaceuticals International To Promote And Distribute Intendis GmbH Dermatological Products In The United Kingdom
10/10/2006
-
Valeant Pharmaceuticals International Previews 24-Week Results Of Direct Trial For InfergenĀ®
10/3/2006
-
Valeant Pharmaceuticals International Reports VISER2 Results For Viramidine(R); Drug Does Not Meet Efficacy Goal
9/12/2006
-
The Day In Review: Valeant Pharmaceuticals International Rises Despite Mixed Trial Results
9/12/2006
-
Valeant Pharmaceuticals International Receives Informal Inquiries From SEC
9/11/2006
-
Valeant Pharmaceuticals International To Present At Bear Stearns 19th Annual Healthcare Conference
9/6/2006